Patents Examined by Terra C. Gibbs
  • Patent number: 11365415
    Abstract: The subject invention provides a pharmaceutical composition comprising an inhibitory RNA (iRNA) that mediates sequence-specific degradation of the mRNA encoding Poly (ADP-ribose) polymerase 1 (PARP1) and methods of treating cancers by administering the pharmaceutical composition to a subject in need thereof. In one embodiment, the iRNA is miR-223, particularly, miR-223-3p or a modified miR-223-3p having substitutions and/or deletions in the sequence of miR-223-3p. In another embodiment, the cancer cells comprise one or more mutations in the genes that mediate homologous recombination DNA repair, for example, BRCA1 and/or BRCA2 genes. The cancer can be breast cancer, ovarian cancer, prostate cancer, pancreatic cancer or meso thelioma. Methods of treating cancer, for example, a cancer comprising BRCA1 and/or 2 mutations, using a combination of iRNA and a second cancer therapeutic are also provided.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 21, 2022
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Robert A. Hromas, Elizabeth Williamson, Gayathri Srinivasan
  • Patent number: 11359202
    Abstract: This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2?-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 14, 2022
    Assignee: Nitto Denko Corporation
    Inventors: Kenjirou Minomi, Jens Harborth, Cima Cina, Wenbin Ying, Jane Zheng, Narendra Vaish
  • Patent number: 11352625
    Abstract: Retrotransposons, operating though human-specific neurological pathways, can contribute to environment, lifestyle, and/or age-related neurodegeneration by disrupting functional mitochondrial populations within neurons. The mitochondrial disruption can occur through a number of retrotransposon-induced mechanisms that can influence the efficient and accurate transcription and/or translation of mitochondrial genes encoded in the nuclear genome, operating primarily through epigenetic processes. Alu element-related conformational changes (both subtle and major) of the outer and inner mitochondrial membrane pores can restrict or prevent the normal translocation of proteins (i.e., TOMM and TIMM complexes), ultimately contributing to mitochondrial stress, mitophagy, inflammation, and neuron and glial cell death.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: June 7, 2022
    Assignee: DUKE UNIVERSITY
    Inventor: Peter Anthony Larsen
  • Patent number: 11351119
    Abstract: The present invention relates to stem cell-derived microvesicles with enhanced efficacy, a use thereof, and a method for enhancing efficacy, and more particularly, to a use of stem cell-derived microvesicles with an enhanced expression level of microRNAs for the prevention or treatment of stroke, and a method for promoting the production of microRNAs of stem cell-derived microvesicles and enhancing efficacy, and a method for promoting the production of stem cell-derived microvesicles and microRNAs within the microvesicles and enhancing the efficacy of stem cells and microvesicles thereof by 3-dimensionally culturing or ischemically stimulating stem cells.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: June 7, 2022
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
    Inventors: Oh Young Bang, Eun Hee Kim, Jae Min Cha
  • Patent number: 11332540
    Abstract: The invention belongs to the field of research and development of genetic engineering antibody drugs, in particular, relates to a method for treating a tumor by administering Circ-CDH1. The Circ-CDH1 is a circular RNA Circ-CDH1 nucleic acid molecule or the protein Circ-CDH1-28 KD expressed by the circular RNA Circ-CDH1 nucleic acid molecule. In particular, a monoclonal antibody Anti-Circ-CDH1 is designed against Circ-CDH1-28 KD, which can specifically detect the content of a protein encoded by endogenous circular RNA Circ-CDH1, can remarkably inhibit invasion and metastasis of cells from tumors such as glioma, breast cancer and the like, and has wide application prospects in clinical detection of tumors and invasion and metastasis treatment.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: May 17, 2022
    Assignee: THE FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY
    Inventor: Nu Zhang
  • Patent number: 11326167
    Abstract: In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGF? signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: May 10, 2022
    Assignee: Yale University
    Inventors: Michael Simons, Pei-Yu Chen
  • Patent number: 11318139
    Abstract: The present invention relates to methods of treating brain metastases using synergistic combinations of anti-PI3K and anti-mTOR therapies. It has also been determined that blocking PI3K and mTOR provides therapeutic benefit for treating brain metastases.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: May 3, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jean Zhao, Jing Ni, Shaozhen Xie
  • Patent number: 11320421
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: May 3, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Patent number: 11312957
    Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: April 26, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Venkitasamy Kesavan, Kallanthottathil Rajeev
  • Patent number: 11298370
    Abstract: The purpose of the present invention is to provide a therapeutic agent which is for inflammatory bowel disease and exhibits superior prophylactic or therapeutic effects on inflammatory bowel disease by using miR-29a and/or miR-29b. The prophylactic or therapeutic agent for inflammatory bowel disease comprises composite particles in which miR-29a and/or miR-29b is/are carried on carbonate apatite particles, and said agent is administered systemically.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: April 12, 2022
    Inventors: Hirofumi Yamamoto, Masaki Mori
  • Patent number: 11286486
    Abstract: The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: March 29, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tracy Zimmermann, Amy Chan, Vasant R. Jadhav, Martin A. Maier, Kallanthottathil G. Rajeev
  • Patent number: 11286488
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: March 29, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
  • Patent number: 11260072
    Abstract: Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: March 1, 2022
    Assignee: 3-D Matrix, Ltd.
    Inventors: Takahiro Ochiya, Tomohiro Fujiwara
  • Patent number: 11246965
    Abstract: Compositions, devices, grafts and methods for reducing or preventing anti-neointima following cardiovascular injuries and interventions are disclosed. The compositions, devices, and grafts typically include an effective amount of a CTP synthase 1 inhibitor to reduce proliferation of vascular smooth muscle cells, without substantial reducing the proliferation of endothelial cells. Methods of reducing neointima formation, accelerating re-endothelialization, and reducing restenosis in a subject using the compositions, devices, and grafts are also disclosed.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: February 15, 2022
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Shiyou Chen, Rui Tang
  • Patent number: 11230714
    Abstract: The presently-disclosed subject matter generally relates to RNAi-based methods and compositions for pest control of the highly invasive Emerald Ash Borer. The disclosed matter also relates to a composition which includes dsRNA directed towards target genes and a method of administering said composition.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 25, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Lynne Rieske-Kinney, Thais Barros Rodrigues
  • Patent number: 11225663
    Abstract: The present invention relates to compositions and methods for detecting motor neuron-specific miRNAs in a population of cells or subject. More particularly, the invention relates to detecting motor neuron-specific miRNAs to detect and treat motor neuron diseases associated with dysregulation of motor neuron-specific miRNAs, such as Amyotrophic Lateral Sclerosis (ALS).
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: January 18, 2022
    Assignee: Washington University
    Inventors: Timothy M. Miller, Mariah Lawler Hoye, Ted Hyman, Erica Koval, Joseph Dougherty
  • Patent number: 11225664
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 18, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
  • Patent number: 11213541
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: January 4, 2022
    Assignee: NEUROVISION PHARMA GMBH
    Inventors: Markus Hossbach, Monika Krampert, Hans-Lothar Arth
  • Patent number: 11198875
    Abstract: A method of modulating hygrosensing and/or thermosensing in an animal, particularly, an insect or disease vector, is provided. Also provided is a method of reducing survival, host-seeking, and/or reproductive capability of an animal, particularly an insect or disease vector. The methods involve an effective amount of an agent that modulates the activity and/or expression of a polynucleotide or polypeptide of an ionotropic receptor (Ir) selected from one or more of Ir25a, Ir93a, Ir40a, Ir68a, or Ir21a. A method of identifying an agent that modulates survival, host-seeking, and/or reproductive capability of an animal, e.g., an insect, is further provided.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: December 14, 2021
    Assignee: BRANDEIS UNIVERSITY
    Inventors: Zachary Knecht, Paul Garrity, Lina Ni
  • Patent number: 11193125
    Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: December 7, 2021
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Yuuichirou Tone, Shin'ichi Takeda, Tetsuya Nagata